Skip to content

Annexon ANNX Total Equity

Total Equity at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$31.42B+6.9%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$1.2B+266%
Omeros logo
OmerosOMER
-$63.33M+70.3%
Vor Biopharma logo
Vor BiopharmaVOR
-$150.42M-328%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$408.73M-30.8%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$576.22M+4,094%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's total equity?
Annexon (ANNX) reported total equity of $204.53M in Q1 2026.
How has Annexon's total equity changed year-over-year?
Annexon's total equity decreased by 16.1% year-over-year, from $243.79M to $204.53M.
What is the long-term trend for Annexon's total equity?
Over 5 years (2020 to 2025), Annexon's total equity has grown at a -9.3% compound annual growth rate (CAGR), from $344.28M to $211.65M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.